MetaCap

BriaCell Therapeutics (BCTX) vs ProMIS Neurosciences (PMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BriaCell Therapeutics (BCTX) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 61.7% versus a loss of 69.9%. Over five years, BCTX leads with a -97.0% price change compared with -98.2% for PMN. ProMIS Neurosciences is the larger company by market cap ($28.4 million vs $26.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCTX-61.75%PMN-69.90%
+146%+32%-82%
Nov 21, 20251 yearNov 20, 2026
BCTX-97.12%PMN-98.38%
+24%-40%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCTX versus PMN key metrics
MetricBCTXPMN
Share price$3.06$3.16
Market cap$26.72M$28.43M
1-day change-3.32%-1.56%
YTD return-56.96%-53.73%
1-year return-61.75%-69.90%
5-year return-97.00%-98.24%
EPS (TTM)$-6.97$-6.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-34.90M$-39.72M
52-week high$13.09$27.40
52-week low$2.60$2.78
Distance from 52-week high-76.62%-88.47%
Analyst consensus—none
Avg. price target upside—+1248.42%
Average volume250.81K164.88K
Shares outstanding8.73M9.00M
Employees—10
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BriaCell Therapeutics

BCTX stock →

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations

About ProMIS Neurosciences

PMN stock →

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

BCTX vs PMN FAQ

Which is bigger, BriaCell Therapeutics or ProMIS Neurosciences?

ProMIS Neurosciences (PMN) is larger, with a market capitalization of $28.43M compared with $26.72M for BriaCell Therapeutics (BCTX).

Which stock has performed better over the past year, BCTX or PMN?

BCTX returned -61.75% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.

Are BriaCell Therapeutics and ProMIS Neurosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons